Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD2 | O14939 | 15/20 | 0.42 |
| ▸ | PLD1 | Q13393 | 15/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000823 | 1.00 | PLD2 (0.42) | PLD2PLD1OPRM1DRD2YEATS4 | |
| SCHEMBL5006625 | 0.98 | PLD2 (0.42) | PLD2PLD1OPRM1DRD2YEATS4 | |
| SCHEMBL4435268 | 0.91 | PLD2 (0.43) | PLD2PLD1OPRM1DRD2HSD11B1 | |
| SCHEMBL4437945 | 0.90 | OPRM1 (0.42) | PLD2PLD1OPRM1DRD2KCNH2 | |
| SCHEMBL4440308 | 0.90 | ADRB2 (0.43) | PLD2PLD1OPRM1KCNH2HSD11B1 | |
| SCHEMBL5000558 | 0.90 | PLD2 (0.42) | PLD2PLD1OPRM1DRD2HSD11B1 | |
| SCHEMBL4444801 | 0.89 | OPRM1 (0.42) | PLD2PLD1OPRM1DRD2KCNH2 | |
| SCHEMBL4440298 | 0.89 | OPRM1 (0.41) | PLD2PLD1OPRM1DRD2KCNH2 | |
| SCHEMBL5006610 | 0.87 | PLD1 (0.35) | PLD2PLD1KCNH2HSD11B1 | |
| SCHEMBL4445833 | 0.87 | YEATS4 (0.44) | PLD2PLD1OPRM1DRD2YEATS4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | claimed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | claimed |
| EP-2121656-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | Pfizer Products Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER INC | 2008-11-20 | — | — | US | disclosed |
| WO-2008084300-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | PFIZER PRODUCTS INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287479-A1 | INHIBITORS OF SERINE PALMITOYLTRANSFERASE | SPTLC1, SPTLC2, CPT1A | PLD2 917/4885PLD1 351/4885OPRM1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.